PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Soleno Therapeutics, Inc. (SLNO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS8342032005
CUSIP834203200
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.64B
EPS-$2.36
PE Ratio83.40
EBITDA (TTM)-$36.71M
Year Range$3.69 - $53.82
Target Price$65.17
Short %16.76%
Short Ratio9.42

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Soleno Therapeutics, Inc.

Popular comparisons: SLNO vs. TRML, SLNO vs. CBZ, SLNO vs. RXST, SLNO vs. SPY, SLNO vs. NVDA, SLNO vs. RIOT, SLNO vs. COST, SLNO vs. PLTR, SLNO vs. IR, SLNO vs. SMCI

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Soleno Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%December2024FebruaryMarchAprilMay
-84.14%
160.05%
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Soleno Therapeutics, Inc. had a return of 14.68% year-to-date (YTD) and 955.09% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date14.68%11.18%
1 month21.79%5.60%
6 months79.12%17.48%
1 year955.09%26.33%
5 years (annualized)9.56%13.16%
10 years (annualized)N/A10.99%

Monthly Returns

The table below presents the monthly returns of SLNO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202415.16%4.25%-11.42%4.35%14.68%
202346.97%-30.24%5.42%57.48%56.38%-18.60%18.88%-4.12%503.48%-19.18%24.78%35.25%1,932.83%
2022-13.41%-8.93%-31.02%-10.36%-19.31%14.63%-7.52%-14.23%-24.09%-40.72%9.09%83.33%-67.80%
20211.55%22.96%-47.72%-3.97%-14.88%10.68%-20.18%0.47%1.12%-19.55%-12.26%-37.17%-78.76%
202017.69%-19.65%-14.39%28.15%10.16%-33.93%-22.52%24.42%17.29%-30.68%12.64%-1.53%-34.35%
20193.51%-16.38%39.19%-2.43%46.77%-5.08%-21.43%-18.64%-16.20%2.00%13.07%69.94%71.93%
2018-1.66%-5.09%7.92%-8.44%25.60%12.23%15.81%-22.51%2.86%-3.24%-7.66%-11.40%-5.00%
20174.94%-23.53%9.23%-15.49%6.65%-21.71%-0.56%23.44%-15.45%-25.77%-24.35%23.29%-55.56%
2016-27.57%-14.18%3.39%2.61%9.02%-12.78%-18.97%9.57%-12.62%14.44%-8.74%-13.83%-56.22%
2015-10.83%373.68%1.59%-1.41%-31.06%-35.40%-22.06%5.48%-8.66%-12.80%8.70%-7.50%24.03%
2014-14.18%-55.21%-61.56%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of SLNO is 98, placing it in the top 2% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of SLNO is 9898
SLNO (Soleno Therapeutics, Inc.)
The Sharpe Ratio Rank of SLNO is 9090Sharpe Ratio Rank
The Sortino Ratio Rank of SLNO is 100100Sortino Ratio Rank
The Omega Ratio Rank of SLNO is 9999Omega Ratio Rank
The Calmar Ratio Rank of SLNO is 100100Calmar Ratio Rank
The Martin Ratio Rank of SLNO is 100100Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Soleno Therapeutics, Inc. (SLNO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


SLNO
Sharpe ratio
The chart of Sharpe ratio for SLNO, currently valued at 1.90, compared to the broader market-2.00-1.000.001.002.003.004.001.90
Sortino ratio
The chart of Sortino ratio for SLNO, currently valued at 11.92, compared to the broader market-4.00-2.000.002.004.006.0011.92
Omega ratio
The chart of Omega ratio for SLNO, currently valued at 2.51, compared to the broader market0.501.001.502.002.51
Calmar ratio
The chart of Calmar ratio for SLNO, currently valued at 9.79, compared to the broader market0.002.004.006.009.79
Martin ratio
The chart of Martin ratio for SLNO, currently valued at 56.95, compared to the broader market-10.000.0010.0020.0030.0056.95
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.38, compared to the broader market-2.00-1.000.001.002.003.004.002.38
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.37, compared to the broader market-4.00-2.000.002.004.006.003.37
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.42, compared to the broader market0.501.001.502.001.42
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.94, compared to the broader market0.002.004.006.001.94
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.12, compared to the broader market-10.000.0010.0020.0030.009.12

Sharpe Ratio

The current Soleno Therapeutics, Inc. Sharpe ratio is 1.90. This value is calculated based on the past 12 months of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Soleno Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00December2024FebruaryMarchAprilMay
1.90
2.38
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Soleno Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-92.97%
-0.09%
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Soleno Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Soleno Therapeutics, Inc. was 99.86%, occurring on Dec 15, 2022. The portfolio has not yet recovered.

The current Soleno Therapeutics, Inc. drawdown is 92.97%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.86%Mar 5, 20151962Dec 15, 2022
-70.79%Nov 18, 201445Jan 27, 201515Feb 18, 201560
-9.74%Feb 27, 20151Feb 27, 20152Mar 3, 20153
-8.56%Feb 19, 20152Feb 20, 20151Feb 23, 20153
-8.35%Feb 25, 20151Feb 25, 20151Feb 26, 20152

Volatility

Volatility Chart

The current Soleno Therapeutics, Inc. volatility is 25.50%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%December2024FebruaryMarchAprilMay
25.50%
3.36%
SLNO (Soleno Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Soleno Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items